AKE Stock Analysis: Arkema | PA
Specialty Chemicals | PA, France | Market Cap: 4.703m EUR | 12M Return: 0.1% | FR0010313833 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 10.9M
EPS Trend: -91.4%
Qual. Beats: 0
Rev. Trend: -82.8%
Qual. Beats: -1
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Arkema S.A. (AKE) is a French specialty materials manufacturer operating across Europe, North America, and Asia, with a presence in approximately 60 countries. The company is structured around three business segments: Adhesive Solutions, Advanced Materials, and Coating Solutions, alongside an Intermediates segment. Its product portfolio spans high-performance polymers (such as specialty polyamides, PVDF, and polyimides), performance additives, acrylics, coating resins, and fluorogases. End-markets served include construction, automotive, packaging, electronics, oil and gas, renewable energy, water treatment, and 3D printing.
The company was incorporated in 2003 and is headquartered in Puteaux, France. Arkema is listed on Euronext Paris and classified within the Diversified Chemicals sub-industry of the Materials sector. Its business model is anchored in specialty rather than commodity chemistry, focusing on high-value applications such as lightweighting, bio-based products, recycling solutions, and new energy technologies, which typically command higher margins and provide resilience against raw material price volatility.
- PVDF and battery materials demand accelerates Advanced Materials revenue growth
- European energy costs and raw material volatility pressure Intermediates segment margins
- Bostik integration expands Adhesive Solutions margins in construction renovation
| Net Income: 60.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA 1.11 > 1.0 |
| NWC/Revenue: 18.41% < 20% (prev 29.58%; Δ -11.17% < -1%) |
| CFO/TA 0.06 > 3% & CFO 915.6m > Net Income 60.0m |
| Net Debt (3.18b) to EBITDA (1.16b): 2.74 < 3 |
| Current Ratio: 1.52 > 1.5 & < 3 |
| Outstanding Shares: last quarter (102.7m) vs 12m ago 35.12% < -2% |
| Gross Margin: 17.83% > 18% (prev 19.02%; Δ -1.19% > 0.5%) |
| Asset Turnover: 63.38% > 50% (prev 67.86%; Δ -4.47% > 0%) |
| Interest Coverage Ratio: 2.54 > 6 (EBIT TTM 332.8m / Interest Expense TTM 130.8m) |
| A: 0.12 (Total Current Assets 4.80b - Total Current Liabilities 3.16b) / Total Assets 14.2b |
| B: 0.30 (Retained Earnings 4.18b / Total Assets 14.2b) |
| C: 0.02 (EBIT TTM 332.8m / Avg Total Assets 14.0b) |
| D: 0.94 (Book Value of Equity 6.78b / Total Liabilities 7.21b) |
| Altman-Z'' = 2.87 = A |
| DSRI: 1.23 (Receivables 1.91b/1.65b, Revenue 8.90b/9.44b) |
| GMI: 1.07 (GM 19.02% / 17.83%) |
| AQI: 0.95 (AQ_t 0.38 / AQ_t-1 0.40) |
| SGI: 0.94 (Revenue 8.90b / 9.44b) |
| TATA: -0.06 (NI 60.0m - CFO 915.6m) / TA 14.2b) |
| Beneish M = -2.85 (Cap -4..+1) = A |
As of August 23, 2026, the stock is trading at EUR 59.20 with a total of 146,916 shares traded. Over the past week, the price has changed by -4.82%, over one month by +8.72%, over three months by +1.84% and over the past year by +0.14%.
Current recommended Stop Loss: 57.10 (which is 3.5% or 1.4 ATR below the current price).
Arkema has no consensus analysts rating.
P/E Trailing = 259.1667
P/E Forward = 14.0647
P/S = 0.5283
P/B = 0.6936
P/EG = 0.4673
Revenue TTM = 8.90b EUR
EBIT TTM = 332.8m EUR
EBITDA TTM = 1.16b EUR
Long Term Debt = 2.61b EUR (from longTermDebt, last quarter)
Short Term Debt = 1.37b EUR (from shortTermDebt, last quarter)
Debt = 4.65b EUR (from shortLongTermDebtTotal, last quarter) + Leases 373.6m
Net Debt = 3.18b EUR (calculated: Debt 4.65b - CCE 1.47b)
Enterprise Value = 7.88b EUR (4.70b + Debt 4.65b - CCE 1.47b)
Interest Coverage Ratio = 2.54 (Ebit TTM 332.8m / Interest Expense TTM 130.8m)
EV/FCF = 21.16x (Enterprise Value 7.88b / FCF TTM 372.5m)
FCF Yield = 4.73% (FCF TTM 372.5m / Enterprise Value 7.88b)
FCF Margin = 4.18% (FCF TTM 372.5m / Revenue TTM 8.90b)
Net Margin = 0.67% (Net Income TTM 60.0m / Revenue TTM 8.90b)
Gross Margin = 17.83% ((Revenue TTM 8.90b - Cost of Revenue TTM 7.31b) / Revenue TTM)
Gross Margin QoQ = 19.99% (prev 17.60%)
Tobins Q-Ratio = 0.56 (Enterprise Value 7.88b / Total Assets 14.2b)
Interest Expense / Debt = 2.82% (Interest Expense 130.8m / Debt 4.65b)
Taxrate = 35.24% (37.6m / 106.7m)
NOPAT = 215.5m (EBIT 332.8m * (1 - 35.24%))
Current Ratio = 1.52 (Total Current Assets 4.80b / Total Current Liabilities 3.16b)
Debt / Equity = 0.69 (Debt 4.65b / totalStockholderEquity, last quarter 6.78b)
Debt / EBITDA = 2.74 (Net Debt 3.18b / EBITDA 1.16b)
Debt / FCF = 8.53 (Net Debt 3.18b / FCF TTM 372.5m)
Total Stockholder Equity = 6.55b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.43% (Net Income 60.0m / Total Assets 14.2b)
RoE = 0.92% (Net Income TTM 60.0m / Total Stockholder Equity 6.55b)
RoCE = 3.63% (EBIT 332.8m / Capital Employed (Equity 6.55b + L.T.Debt 2.61b))
RoIC = 1.81% (NOPAT 215.5m / Invested Capital 11.9b)
WACC = 5.04% (E(4.70b)/V(9.35b) * Re(8.22%) + D(4.65b)/V(9.35b) * Rd(2.82%) * (1-Tc(0.35)))
Discount Rate = 8.22% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 47.26 | Cagr: 14.94%
[DCF] Terminal Value 77.97% ; FCFF base≈307.9m ; Y1≈353.0m ; Y5≈519.5m
[DCF] Fair Price = 61.35 (EV 7.82b - Net Debt 3.18b = Equity 4.64b / Shares 75.6m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -91.40 | EPS CAGR: -27.96% | SUE: 0.23 | # QB: 0
Revenue Correlation: -82.77 | Revenue CAGR: -2.76% | SUE: -3.17 | # QB: -1
EPS current Quarter (2026-09-30): EPS=1.47 | Chg30d=+6.78% | Revisions=+25% | Analysts=3
EPS current Year (2026-12-31): EPS=4.54 | Chg30d=-2.20% | Revisions=+22% | GrowthEPS=+5.1% | GrowthRev=+1.2%
EPS next Year (2027-12-31): EPS=5.60 | Chg30d=-5.33% | Revisions=-30% | GrowthEPS=+23.3% | GrowthRev=+1.6%
[Analyst] Revisions Ratio: +0% (up=7, down=7)